Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113491 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL30327955 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL145251 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL120496 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL145249 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL428868 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL2745491 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL24062219 | 0.96 | ALDH1A1 (0.37) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| Hydrochloric Acid SCHEMBL4083778 | 0.96 | ALDH1A1 (0.30) | ALDH1A1HSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL31511693 | 0.96 | ALDH1A1 (0.30) | ALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233853-A1 | A PROCESS FOR PREPARING HALOGENATED AZAINDOLE COMPOUNDS USING BOROXINE | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2017-10-25 | — | — | EP | claimed |
| WO-2016100633-A1 | A PROCESS FOR PREPARING HALOGENATED AZAINDOLE COMPOUNDS USING BOROXINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-23 | — | — | WO | claimed |
| WO-2016100625-A1 | A PROCESS FOR PREPARING HALOGENATED AZAINDOLE COMPOUNDS USING BOROXINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-23 | — | — | WO | claimed |
| EP-1390340-A4 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INST TECHNOLOGY (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1390340-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-02-25 | — | — | EP | claimed |
| WO-2002085838-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-10-31 | — | — | WO | claimed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4709718-A1 | 6-SUBSTITUTED-3-PHENYL-ISOINDOLIN-1-ONES AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | Genentech Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2025-07-10 | — | — | US | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NodThera Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| WO-2010034110-A1 | BETA-CARBOLINE SULPHONYLUREA DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2010-04-01 | — | — | WO | disclosed |
| EP-2121598-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-11-25 | — | — | EP | disclosed |
| US-20090275592-A1 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008076754-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2008-06-26 | — | — | WO | disclosed |
| EP-1534671-A4 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INST TECHNOLOGY (US) | 2007-10-24 | — | — | EP | disclosed |
| EP-1534671-A2 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004013094-A2 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NLRP3, NOD1, NLRP1 | ALDH1A1 961/4885HSD17B10 2531/4885KDM4E 3974/4885 |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | ALDH1A1 961/4885HSD17B10 2531/4885KDM4E 3974/4885 |
| US-20090275592-A1 | Heterocyclic modulators of PKB | MTOR, PDK1, EIF4EBP1 | ALDH1A1 3902/4885HSD17B10 1199/4885KDM4E 2597/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | ALDH1A1 79/4885HSD17B10 1586/4885KDM4E 1882/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | ALDH1A1 128/4885HSD17B10 1375/4885KDM4E 3895/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | ALDH1A1 128/4885HSD17B10 1375/4885KDM4E 3895/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | ALDH1A1 100/4885HSD17B10 410/4885KDM4E 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.